Annovis Bio Inc. (ANVS)
1.50
-0.15 (-9.09%)
At close: Mar 31, 2025, 3:59 PM
1.52
1.67%
After-hours: Mar 31, 2025, 07:45 PM EDT
-9.09% (1D)
| Bid | 1.46 |
| Market Cap | 29.13M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -17.87B |
| EPS (ttm) | -2.31 |
| PE Ratio (ttm) | -0.65 |
| Forward PE | -5.59 |
| Analyst | Buy |
| Ask | 1.52 |
| Volume | 338,488 |
| Avg. Volume (20D) | 512,825 |
| Open | 1.70 |
| Previous Close | 1.65 |
| Day's Range | 1.43 - 1.70 |
| 52-Week Range | 1.43 - 20.00 |
| Beta | 1.65 |
About ANVS
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for prote...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 29, 2020
Employees 8
Stock Exchange NYSE
Ticker Symbol ANVS
Website https://www.annovisbio.com
Analyst Forecast
According to 6 analyst ratings, the average rating for ANVS stock is "Buy." The 12-month stock price forecast is $25.5, which is an increase of 1605.69% from the latest price.
Stock Forecasts1 month ago
-6.8%
Annovis Bio shares are trading lower after D. Bora...
Unlock content with
Pro Subscription
1 month ago
-33.47%
Annovis Bio shares are trading lower after the company announced a $21 million public offering.
